Patient-specific renal cell carcinoma antigens presented on dendritic cell MHC molecules (RCC-DC antigen-MHC complex)

This target represents the personalized repertoire of tumor-associated antigens (TAAs) and neoantigens derived from a patient's renal cell carcinoma (RCC) and presented on the surface of dendritic cells (DCs) via Major Histocompatibility Complex (MHC) molecules (IntechOpen, 2018; NIH, 2004). In the context of immunotherapy, DCs are loaded with these patient-specific antigens—often through tumor lysate pulsing, RNA electroporation, or fusion—to serve as a potent vaccine (BMJ, 2015; NIH, 2004). The resulting MHC-peptide complexes are recognized by the T-cell receptors (TCRs) of naive and memory T cells, triggering a targeted immune response against the malignancy (Targeted Oncology, 2013; AACR, 1999). This approach aims to overcome the immunosuppressive environment of RCC by providing high-density antigen presentation and essential co-stimulatory signals like CD40L (IntechOpen, 2018; NIH, 2016). Therapeutic agents like AGS-003 (Rocapuldencel-T) utilize this mechanism to expand the population of tumor-specific cytotoxic T lymphocytes (CTLs), thereby improving clinical outcomes such as progression-free and overall survival in metastatic RCC patients (BMJ, 2015; Urology Times, 2021).

Other names

Tumor-associated antigens (TAAs)NeoantigensAutologous tumor antigensRCC-specific antigensMHC-peptide complexesTumor-specific antigens (TSAs)

Induction of tumor-specific cytotoxic T lymphocytes (CTLs) and helper T cells (Th1) through the presentation of patient-derived antigens on MHC class I and II molecules, accompanied by co-stimulatory signals to activate the adaptive immune system against renal cell carcinoma.